reason report
zolgensma spinraza takeaway earn
bottom line spinraza zolgensma revenu beat
expect first full quarter zolgensma sale reflect
sizeabl spinal muscular atrophi sma market opportun ex-
us geographi despit zolgensma updat us exceed
expect spinraza put strong q/q revenu growth ad
sma patient spinraza treatment ou updat
model today disclosur partner mp
spinraza revenu partner nv zolgensma revenu
increas estim model updat leav
price target unchang reiter market perform rate
share
strong start zolgensma us growth beyond
expect driven approv ex-u geographi earli sign
patient bolu like play next quarter
treat patient previous treat spinraza sinc
on-label use zolgensma limit patient younger year
old expect preval patient pool quickli dri revenu
increasingli depend penetr incid patient identifi
newborn screen nv indic expect rate
newborn screen us increas substanti end
signific sourc growth zolgensma along expans
ou geographi potenti approv anticip eu
japan manag provid exact patient count
gross/net discount zolgensma indic rang
patient treat zolgensma sinc launch major
us patient select european countri
institut paid program
new ou patient top patient ad indic
rapid penetr new market though larg volum new
patient add shift patient mix toward market lower price
power revenu trend indic spinraza discount outsid
us stabil rel us price us spinraza continu find
new patient new patient add line number disclos last
quarter offset switch zolgensma
continu believ intrathec zolgensma risdiplam roch
much larger threat spinraza instal base iv zolgensma
number preval patient year younger elig
zolgensma collaps within coupl quarter
compani inform svb leerink llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
chang sma model amend sma market model
allow patient current treat spinraza switch zolgensma
previous explicitli model switch spinraza
zolgensma approv intrathec formul
increas us zolgensma penetr match nv expect
zolgensma revenu line revenu quarter
estim increas full-year revenu
penetr spinraza us market increment
increas match patient flow disclos ou revenu
adjust reflect increas share ww revenu
chang bring spinraza revenu estim
full year spinraza estim
rate share market perform fan shareholder-friendli strategi
see attract risk/reward profil earli pipelin worri mid- near-term
consensu number come pressur competit product launch data
readout next year half combin competit environ
earli partner strategi go forward sidelin share current level
month price target per share base discount cash flow methodolog
forecast sale tegsedi royalti spinraza on-going revenu risk-adjust
sale royalti key pipelin agent partner program explicitli model expens
result cash flow assum discount rate consist
compani coverag univers revenu gener approv product
wholly-own independ commerci least one end-market termin
growth rate addit factor ionss net cash balanc valuat
risk view outlook valuat includ major chang price
reimburs coverag unit state europ rare diseas drug tegsedi
spinraza compani key pipelin drug forecast tegsedi also subject
risk better-than-expect market share patisiran tafamidi unmodel
competit entrant use disrupt technolog gene edit risk
includ clinic regulatori disappoint pipelin excess factor
probabl adjust addit sale profit fail match estim ioni
unabl continu secur cash flow gener research develop partnership
line forecast dilut financ may requir order support futur commerci
oper clinic develop pipelin agent
rate share market perform see headlin risk nvs/avx preclin
data manipul scandal broadli appreci investor remain optimist
zolgensma blockbust see current valuat adequ account robust
royalti stream zolgensma partner asset well compani wholli
own pipelin see crowd competit landscap challeng clinic practic
wet unclear commerci potenti
mucopolysaccharidos type ii mp mp ii clinic meaning data
homozyg famili hypercholesterolemia hofh yet disclos though see
robust clinic scientif rational program cautious optimist
futur data would justifi valu ascrib asset addit compani strong
cash posit potenti non-dilut capit ip licens posit limit balanc
sheet risk due mix risk/reward profil share across program near-
mid-term catalyst consid collect find difficult compellingli argu investor
deploy fresh capit either long short basi present
price target base dcf methodolog forecast risk-
adjust sale risk-adjust royalti
key partner program explicitli model expens result cash flow
assum discount rate consist clinic stage pre-revenu compani
coverag univers termin growth rate addit includ rgnx net cash
balanc valuat
risk view outlook valuat inc includ major chang
price reimburs coverag gene therapi agent unexpect safeti efficaci
signal clinic develop chang regulatori environ forecast subject
unmodel competitor entrant includ gene edit disrupt technolog
could potenti compet share aav-bas therapi develop partner
convers sale royalti forecast includ estim impact certain competit
agent agent fail enter market poorer-than-expect clinic profil
otherwis fail garner share expect could repres materi upsid
estim element compani busi model depend monet
core ip asset chang intellectu properti law enforc compani ip
portfolio could materi impact compani prospect futur cash flow
research collabor
sale royalti
licens royalti p/w
portion akcea split
equiti net loss regulu unc
loss invest
net incom attribut
dilut ep attribut
ownership
compani report svb leerink estim
inotersen scenario subq hattr
inotersen scenario subq hattr wtttr
scenario subq hattr
scenario subq hattr wtttr
scenario risdiplam broad label
scenario risdiplam fail sma
spinraza royalti
ww royalties/profit share ioni p/w
total p/w royalti ioni
compani report svb leerink estim
inotersen
volanesorsen sale
akcea-apociii-lrx royalti
ackea-apo -lrx royalti
compani report svb leerink estim
brand
type event
event trial detail
cardiovascular outcom studi initi
expect
svb leerink llc equiti research compani file
total cost revenu
research develop
gener administr
sale market
loss incom oper
interest incom licens
total incom expens
loss incom tax
compani report svb leerink equiti research estim
bs mm
cash equival
properti equip net
accru expens current liabil
defer rent net current portion
accumul comprehens loss incom
total liabil stockhold equiti
compani report svb leerink equiti research estim
chang
oper
net amort premium accret discount market debt secur
invest
financ
proce exercis stock option
compani report svb leerink equiti research estim
scenario risdiplam succe type ii/iii sma
scenario risdiplam fail type ii/iii sma
royalti
ww royalties/profit share p/w
total p/w royalti
compani report svb leerink equiti research estim
univers pennsylvania
univers minnosota
compani report svb leerink equiti research estim
brand
type event
event trial detail
expect
initi phase iib trial
addit data updat cohort cohort
cohort
submiss ind form batten
svb leerink llc equiti research compani file
complet pivot strong studi type
anticip us file intrathec zolgensma
chmp decis iv zolgensma
potenti approv iv zolgensma japan
